CDA data reveals trends on drug approvals and reimbursements in Canada
In April 2026, Canada’s Drug Agency (CDA) released an expanded data set offering insights and trends within its regulatory system…
Pricing and Market Access
Healthcare cost inflation is back in the headlines
Japan’s FY26 price revision expands G1 repricing and drives price reduction
MFN changing the rules of the game for the Nordic countries
The Most Favored Nation Policy: early insights into Europe’s response
GlobalData’s key thoughts from World EPA Congress 2026
Market instability expected from South Korea’s new pricing reform in 2026-2028
Have originator medicines’ list prices started to drop in the US?
